AIM
PRVB

Alambic Investment Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Alambic Investment Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,189
Closed -$30K – 404
2019
Q1 		$30K Sell
13,189
-3,300
-20% -$7.75K 0.01% 342
2018
Q4 		$29K Buy
+16,489
New +$47.4K 0.01% 299

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
IG
ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return

Alambic Investment Management's PRVB Position: Q2 2019 in Review

Alambic Investment Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2019, closing a stake of 13,189 shares — an estimated $30K sold.

Alambic Investment Management first reported a position in PRVB in Q4 2018 and held it in 2 quarters. The position peaked at $30K in Q1 2019. 28 funds tracked by Wall St. Rank hold PRVB as of Q2 2019.

  • Alambic Investment Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Alambic Investment Management sold 13,189 Provention Bio, Inc. Common Stock shares in Q2 2019, an estimated $30K.
  • Alambic Investment Management first reported a position in Provention Bio, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Alambic Investment Management's Provention Bio, Inc. Common Stock position peaked at $30K in Q1 2019.
  • 28 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2019.

Based on Alambic Investment Management's 13F filing for Q2 2019, filed 13 Aug 2019.